Evidence map›Paper›PMID 38178775›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2024

Project Confirm: Accelerated Drug Approvals for CML-Letter.

Jan H Beumer, Salvatore J Salamone

Abstract readLetterComment
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Jan H BeumerCancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.ORCID 0000-0002-8978-9401
Salvatore J SalamoneSaladax Biomedical Inc., Bethlehem, Pennsylvania.ORCID 0009-0001-6561-2417

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0M
NCI ET-CTN with Phase i Emphasis at UPCIUM1CA186690 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD, Farshid Dayyani · 2014 to 2026
$9.1M
PITT-CAL ETCTN PK Resource LaboratoryU24CA247643 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI TIMOTHY W SYNOLD, Raman Venkataramanan · 2020 to 2026
$3.6M
NCI NIH HHS P30 CA047904NCI NIH HHS U24 CA247643NCI NIH HHS UM1 CA186690
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug ApprovalLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHumansUnited StatesUnited States Food and Drug Administration

Identifiers

PMID38178775
PMCPMC10783536

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.